PHARMACOKINETICS OF SECOND LINE ANTI-TB DRUG (LEVOFLOXACIN) IN MDR-TB PATIENTS. (2019). Scholar: National School of Leadership, 8(2.2). https://jconsortium.com/index.php/scholar/article/view/93